CFDE Data Portal | Search LOC105371256

	Label	Description
	LOC105371256 Gene (Entity type)	ENSG00000285367 - uncharacterized LOC105371256
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE161800 cisplatin A-549 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 12 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216274 GSE216292 palbociclib 4 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 5 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 gemcitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105371256

ENSG00000285367 - uncharacterized LOC105371256

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 5 human dn

A Gene Set from LINCS

GSE161800 cisplatin A-549 0 v 2 human up

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 12 v 1 human dn

A Gene Set from LINCS

GSE113655 phenol 5 v 4 human dn

A Gene Set from LINCS

GSE216274 GSE216292 palbociclib 4 v 2 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 3 v 6 human up

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 5 v 1 human dn

A Gene Set from LINCS

GSE148200 gemcitabine 1 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.